Results 171 to 180 of about 1,856,875 (191)

Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure

Journal of Cardiac Failure, 2023
Soluble urokinase-type plasminogen activator receptor (suPAR) is a marker of immune activation and pathogenic factor for kidney disease shown to predict cardiovascular outcomes including heart failure (HF) in various populations. We characterized suPAR levels in patients with HF and compared its ability to discriminate risk to that of B-type ...
Salim S. Hayek, Ayman Samman Tahhan, Yi-An Ko, Ayman Alkhoder, Shuai Zheng, Ravila Bhimani, Joy Hartsfield, Jonathan Kim, Peter Wilson, Leslee Shaw, Changli Wei, Jochen Reiser, Arshed A. Quyyumi   +12 more
openaire   +2 more sources

Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis [PDF]

Joint Bone Spine, 2013
Recent studies demonstrated that soluble urokinase plasminogen activator receptor (suPAR) is a valuable marker in the recognition of an inflammatory response. Ongoing inflammation leads to elevated plasma suPAR levels. We aimed to characterize plasma suPAR levels in ankylosing spondylitis (AS) patients compared to healthy individuals in order to reveal
Toldi, Gergely, Szalay, Balázs, Bekő, Gabriella, Kovács, László, Vásárhelyi, Barna, Balog, Attila   +5 more
openaire   +3 more sources

Soluble urokinase‐type plasminogen activator receptor is associated with signs of periodontitis in adolescents

European Journal of Oral Sciences, 2018
Owing to its molecular stability in body fluids, soluble urokinase‐type plasminogen activator receptor (suPAR) is used as a biomarker for the level of systemic inflammation. This study compares the suPAR levels in serum with those in the saliva of adolescents and evaluates their association with the periodontal conditions.
Peter D. Skottrup, Gunnar Dahlén, Vibeke Baelum, Rodrigo Lopez   +3 more
openaire   +3 more sources

Soluble urokinase plasminogen activator receptor (suPAR) promotes atherosclerosis

Kidney International, 2023
Tilman B. Drueke, Ziad A. Massy
openaire   +2 more sources

Soluble Receptor for Urokinase Plasminogen Activator in Community-Acquired Pneumonia in Children

2013
Community-acquired pneumonia (CAP) is a leading single cause of mortality in children under 5 years of age. In search of new diagnostic markers, soluble urokinase plasminogen activator receptor (suPAR) seems to offer promise as a novel clinical tool. The goal of the present study was to assess the relation between suPAR and the severity of CAP.
A, Wrotek, K, Pawlik, T, Jackowska
openaire   +2 more sources

Serum Soluble Urokinase Plasminogen Activator Receptor in Diabetic Nephropathy

QJM: An International Journal of Medicine
Abstract Background Diabetes mellitus (DM) is a rapidly growing global health problem. Persistent hyperglycemia in uncontrolled DM can cause several complications including diabetic retinopathy and nephropathy.
Eman El-Sayed Ahmed, Hoda Mohamed El-Sayed, Lamyaa Salem, Haidy Ahmed Fouad, Hossam Moustafa ElKady   +4 more
openaire   +1 more source

Elevated Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 Patients

Clinical Chemistry and Laboratory Medicine, 2021
Giuseppe Lippi, Brandon Michael Henry
exaly  

Soluble Urokinase‐Type Plasminogen Activator Receptor, Changes of 24‐Hour Blood Pressure, and Progression of Chronic Kidney Disease

Journal of the American Heart Association, 2021
Sungha Park, Seung Hyeok Han, Jong Hyun Jhee   +2 more
exaly  

Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor‐1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans

Journal of the American Heart Association, 2018
Michel T Corban, Abhiram Prasad
exaly  

Soluble Urokinase Plasminogen Activator Receptor in Plasma Is Associated With Incidence of CVD. Results From the Malmö Diet and Cancer Study

Atherosclerosis, 2012
Gunnar Engström, Harry Björkbacka, B Hedblad   +2 more
exaly